Loading...
Recent clinical trials have established the efficacy of chimeric antigen receptor (CAR) T-cell and T-cell–engaging bispecific antibodies that cotarget myeloma cell-surface antigens. Now, investigators report the multicenter, industry-funded, phase 1–2 MajesTEC-1 study of teclistamab, a bispecific antibody that binds CD3 on T cells and the B-cell maturation antigen on myeloma cells.
Patients with refractory or relapsed disease after at least three lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody) received weekly subcutaneous injections of teclistamab. An initial stepped-up dosing phase and the first full dose were given in hospital to mitigate cytokine release syndrome (CRS).
A total of 1…